Newly added funding closes critical gap and enables planned trial initiation in early 2026

Beacon Therapeutics has treated the first patient in a new clinical trial evaluating bilateral gene therapy for X-linked retinitis pigmentosa. This milestone builds on encouraging earlier data and represents continued momentum in retinal gene therapy research — bringing renewed hope to families affected by inherited retinal diseases.

The FDA has approved the first-ever gene therapy for Wiskott-Aldrich syndrome, marking a major milestone for the rare disease community. While this treatment is not for vision loss, it represents important progress for gene therapy as a whole — and brings renewed hope for families awaiting treatments for inherited retinal diseases like BBS and retinitis pigmentosa.

Patient advocacy is now one of the most powerful drivers of progress in retinal gene therapy. Learn how nonprofit involvement, family voices, awareness, and fundraising are accelerating research for Bardet-Biedl Syndrome and inherited retinal diseases — and why this work matters now more than ever.